Cingulate Inc. (CING): Shareholders' Equity
$2.51M
As of 2025-12-31
$23.47M
As of 2026-06-30
-13.5%
3-year compound annual growth
+14.2%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.51M | -66.3% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $7.46M | n/m | 2026-03-18, Balance as of period end |
| 2023-12-31 | -$6.87M | n/m | 2025-03-27, Balance as of period end |
| 2022-12-31 | $3.88M | -81.4% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $20.84M | n/m | 2023-03-10, Balance as of period end |
| 2020-12-31 | $1.29M | n/a | 2022-03-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Cingulate Inc. (CING) | 2025-12-31 | $2.51M | -66.3% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $8.54M | -40.3% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $11.86M | -7.0% |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $8.65M | +964.2% |
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | $12.44M | -35.6% |
| Biovie Inc. (BIVI) | 2026-06-30 | $10.27M | -46.0% |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $15.16M | -24.2% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $3.93M | -42.0% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $7.92M | n/m |
Compare CING, CLRB, SYBX, RVPH side by side · Screen every company in Pharmaceutical Preparations ↗